Evidence map›Paper›PMID 42246569›Full record

ArticleThe Journal of infectious diseases2026

What is the Optimal RSV Immunization Strategy for Infants Born in the RSV Off-season?

Hannah C Moore, Damien Foo, Fiona Giannini, Cara Minney-Smith, Christopher C Blyth, Peter C Richmond, Paul Effler, Mohinder Sarna, STAMP RSV Investigators, the

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hannah C MooreWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, The University of Western Australia, Nedlands, Western Australia, Australia.ORCID 0000-0001-6434-8290
Damien FooWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, The University of Western Australia, Nedlands, Western Australia, Australia.ORCID 0000-0002-9396-6060
Fiona GianniniWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, The University of Western Australia, Nedlands, Western Australia, Australia.ORCID 0000-0001-6302-506X
Cara Minney-SmithPathWest Laboratory Medicine, QEII Medical Centre, Nedlands, Western Australia, Australia.
Christopher C BlythWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, The University of Western Australia, Nedlands, Western Australia, Australia.
Peter C RichmondWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, The University of Western Australia, Nedlands, Western Australia, Australia.ORCID 0000-0001-7562-7228
Paul EfflerSchool of Medicine, University of Western Australia, Nedlands, Western Australia, Australia.ORCID 0000-0002-8890-4201
Mohinder SarnaWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, The University of Western Australia, Nedlands, Western Australia, Australia.
STAMP RSV Investigators
the

Funding

BrightSpark Foundation Early Career Research FellowshipCurtin UniversitySTAMP RSV ProgramStan Perron Charitable Foundation 00046ProgPartStan Perron Charitable Foundation Fellowship
6 · The paper itself

Abstract

We explored age-specific infant respiratory syncytial virus (RSV) laboratory-confirmed hospitalization rates by birth month in Western Australia. Population-based analyses were supplemented with susceptible-exposed-infected-recovered-(susceptible) mathematical model simulations. RSV-hospitalizations peaked for infants aged 1-3 months born in-season and 6-10 months born out-of-season, that is spring and summer-born infants. Offering an additional nirsevimab dose to spring and summer-born infants could avert significant hospitalizations and healthcare costs.

Indexed as

ImmunizationRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesHospitalizationHumansInfantInfant, NewbornModels, TheoreticalSeasonsWestern AustraliaRespiratory Syncytial Virus Vaccineshospitalizationimmunizationinfantrespiratory syncytial virus (RSV)seasonality

Identifiers

PMID42246569
PMCPMC13668356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.